1. Home
  2. GRI vs WORX Comparison

GRI vs WORX Comparison

Compare GRI & WORX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRI
  • WORX
  • Stock Information
  • Founded
  • GRI 2018
  • WORX N/A
  • Country
  • GRI United States
  • WORX United States
  • Employees
  • GRI N/A
  • WORX N/A
  • Industry
  • GRI Biotechnology: Pharmaceutical Preparations
  • WORX Services-Misc. Amusement & Recreation
  • Sector
  • GRI Health Care
  • WORX Consumer Discretionary
  • Exchange
  • GRI Nasdaq
  • WORX Nasdaq
  • Market Cap
  • GRI 4.3M
  • WORX 3.6M
  • IPO Year
  • GRI N/A
  • WORX N/A
  • Fundamental
  • Price
  • GRI $1.64
  • WORX $0.28
  • Analyst Decision
  • GRI Strong Buy
  • WORX
  • Analyst Count
  • GRI 2
  • WORX 0
  • Target Price
  • GRI $22.50
  • WORX N/A
  • AVG Volume (30 Days)
  • GRI 175.4K
  • WORX 41.0M
  • Earning Date
  • GRI 11-14-2025
  • WORX 11-14-2025
  • Dividend Yield
  • GRI N/A
  • WORX N/A
  • EPS Growth
  • GRI N/A
  • WORX N/A
  • EPS
  • GRI N/A
  • WORX N/A
  • Revenue
  • GRI N/A
  • WORX $2,838,404.00
  • Revenue This Year
  • GRI N/A
  • WORX N/A
  • Revenue Next Year
  • GRI N/A
  • WORX N/A
  • P/E Ratio
  • GRI N/A
  • WORX N/A
  • Revenue Growth
  • GRI N/A
  • WORX N/A
  • 52 Week Low
  • GRI $1.10
  • WORX $0.26
  • 52 Week High
  • GRI $17.51
  • WORX $3.31
  • Technical
  • Relative Strength Index (RSI)
  • GRI 41.46
  • WORX 47.24
  • Support Level
  • GRI $1.60
  • WORX $0.27
  • Resistance Level
  • GRI $1.79
  • WORX $0.66
  • Average True Range (ATR)
  • GRI 0.17
  • WORX 0.05
  • MACD
  • GRI -0.04
  • WORX 0.00
  • Stochastic Oscillator
  • GRI 7.25
  • WORX 3.83

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About WORX SCWorx Corp.

SCWorx Corp is a provider of data content and services related to the repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. Its software enables a healthcare provider to simplify and organize its data, allows the data to be utilized across multiple internal software applications, and provides the basis for sophisticated data analytics. The company has developed and markets healthcare information technology solutions and associated services to improve healthcare processes and information flow within hospitals and other healthcare facilities.

Share on Social Networks: